

CELLIANT TECHNOLOGY / SUMMARY OF CLINICAL STUDIES

HOLOGENIX, LLC

DATE	TITLE	PRINCIPAL INVESTIGATOR	SPONSORING INSTITUTION	SUMMARY RESULTS	STATUS	NUMBER OF SUBJECTS
2011-2012	Evaluation of a Novel Optically Active Garment with Celliant Fiber on TCPO2 Levels In Healthy Subjects	Dr. Matt Beekley / Dr. Michael Coyle / Dr. Jim Brown	University of Indianapolis Human Performance Laboratory	Pending	Undergoing Data Analysis	100
2012	Effect of Celliant Materials on Pain and Strength with Chronic Elbow and Wrist Pain	Dr. Ian Gordon	University of CA, Irvine Long Beach Veteran's Affairs Medical Center	Pending	In Clinical Testing	80
2011	Influence of Celliant on Athlete Performance & Recovery	Dr. Darren Stefanyshyn / Dr. Jay Worobets	University of Calgary Human Performance Laboratory	Subjects used less oxygen to accomplish the same amount of work. This increases both the performance and efficiency of athletes.	Pending Publication	12
2008-2011	Double blind, placebo controlled, crossover trial on the effect of Optically Modified Polyethylene Terephthalate Fiber mattress covers on sleep disturbances in patients with chronic back pain	Dr. Marcel Hungs / Dr. Annabel Wang	University of CA, Irvine Medical Center, Orange CA	Nighttime awakenings, sleep quality, and sleep efficiency improved. Findings significant enough to expand study.	Undergoing Data Analysis	12
2009	Effect of Garment with 42% Celliant™ fiber on TCPO2 Levels and Grip Strength in Healthy Subjects	Dr. Ian Gordon	University of CA, Irvine Long Beach Veteran's Affairs Medical Center	An average TCPO2 gain of 7% and an average gain in grip strength of 12%.	Abstract	51
2009	Effect of Optically Modified Polyethylene Terephthalate Fiber Socks on Chronic Foot Pain	Dr. Ian Gordon / Dr. Robyn York	University of CA, Irvine Medical Center, Orange CA	Statistically significant reduction of pain and improved comfort for subjects.	Published	55
2005	Celliant Study of Thirteen (13) Healthy Subjects	Dr. Graham McClue	University of Texas A&M Houston, Texas	An average increase in TCPO2 levels from 10% to 24%.	Abstract	13

CELLIANT TECHNOLOGY / SUMMARY OF CLINICAL STUDIES CONTINUED

HOLOGENIX, LLC

DATE	TITLE	PRINCIPAL INVESTIGATOR	SPONSORING INSTITUTION	SUMMARY RESULTS	STATUS	NUMBER OF SUBJECTS
2003	Improving Blood Flow with Celliant in the Hands and Feet of High-Risk Diabetics	Dr. Lawrence Lavery	Loyola University Chicago, Chicago, IL	An average increase in TCPO2 levels from 12% in the hands and 8% in the feet.	Abstract	20

CELLIANT TECHNOLOGY / SUMMARY OF CLINICAL STUDIES UNDER DEVELOPMENT

DATE	TITLE	PRINCIPAL INVESTIGATOR	SPONSORING INSTITUTION	SUMMARY RESULTS	STATUS	NUMBER OF SUBJECTS
2012	Evaluation of a Novel Exercise Garment on Metabolic and Ventilatory Measures During Submaximal Exercise Bouts and During Exercise Recovery	Dr. Matt Beekley / Dr. Michael Coyle	University of Indianapolis Human Performance Laboratory	Pending	In Design	6
2012	Effects of Celliant on Foot Neuropathy	Dr. Mark Warren	Florida Atlantic University	Pending	In Design	TBD
2012	The Sleep Effects of a Mattress Cover Made with Optically Vaso-Active Fibers	Dr. Tom Roth / Dr. Christopher Drake	Henry Ford Hospital, Detroit MI	Pending	In Design	TBD
2012	Biological Basis of Wound Healing with Celliant Wound Dressing	Dr. Lawrence Lavery	University of Texas Southwestern Medical Center at Dallas	Pending	In Design	TBD
2012	The use of quantum dots as a biomarker for increased circulation	Dr. Shimon Weiss	UCLA dept. of Chemistry and Biochemistry	Pending	In Design	TBD